Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
Cassava Sciences (NASDAQ: SAVA) has been the ultimate zero-to-hero biotech stock. Over the past year, shares have gained a stunning 3,630%. The company went from a virtual nobody to an innovator seemingly capable of developing the next Alzheimer's drug to market.
Not everyone believes in Cassava's potential, however. Short interest has remained consistently high at 10% of shares outstanding -- even after the run-up. So can this mid-cap biotech with just one office location and nine employees succeed where industry leaders have failed?
Image source: Getty Images.
Source Fool.com
